Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three ...

A three-drug combination may be effective for patients with EGFR -mutant advanced non-small cell lung cancer (NSCLC) who ...

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

Lung squamous cell carcinoma, the second most common form of non-small cell lung cancer, has long frustrated oncologists with its stubborn resistance to targeted therapy. Now a team of researchers in ...

The double vision can be a symptom of tumors affecting the eye muscles or nerves; the changes in eye appearance, ie, a sunken or bulging eye might be a sign of a tumor in the orbit.Horner's syndrome ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...

FDA issued a complete response letter citing inspection-based compliance findings at Catalent’s Indiana fill-finish site, now owned by Novo Nordisk, as the lone approvability barrier. POD1UM-304 met ...

A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.

Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial. The company's shares were halted in ...

Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial ...